126 related articles for article (PubMed ID: 18024860)
1. Bevacizumab for the treatment of epithelial ovarian cancer: will this be its finest hour?
Kaye SB
J Clin Oncol; 2007 Nov; 25(33):5150-2. PubMed ID: 18024860
[No Abstract] [Full Text] [Related]
2. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.
Cannistra SA; Matulonis UA; Penson RT; Hambleton J; Dupont J; Mackey H; Douglas J; Burger RA; Armstrong D; Wenham R; McGuire W
J Clin Oncol; 2007 Nov; 25(33):5180-6. PubMed ID: 18024865
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab in ovarian cancer.
Mountzios G; Pentheroudakis G
N Engl J Med; 2012 Mar; 366(13):1257; author reply 1258. PubMed ID: 22455430
[No Abstract] [Full Text] [Related]
4. Bevacizumab in ovarian cancer.
Copur MS; Obermiller AM; Ramaekers R
N Engl J Med; 2012 Mar; 366(13):1256-7; author reply 1257-8. PubMed ID: 22455429
[No Abstract] [Full Text] [Related]
5. Bevacizumab in ovarian cancer.
Korn EL; Freidlin B; Abrams JS
N Engl J Med; 2012 Mar; 366(13):1256; author reply 1257-8. PubMed ID: 22455428
[No Abstract] [Full Text] [Related]
6. A case of progressive mucinous ovarian cancer of low malignant potential responsive to biologic therapy with Bevacizumab.
Winer I; Buckanovich RJ
Gynecol Oncol; 2010 Mar; 116(3):578-9. PubMed ID: 19897232
[No Abstract] [Full Text] [Related]
7. Pulmonary hypertension in two patients treated with bevacizumab for recurrent ovarian cancer.
Liotta M; Rose PG; Escobar PF
Gynecol Oncol; 2009 Nov; 115(2):308-9. PubMed ID: 19740533
[No Abstract] [Full Text] [Related]
8. Challenges to the paclitaxel/carboplatin algorithm in ovarian cancer treatment.
Zorn KK
Oncology (Williston Park); 2010 Jul; 24(8):738, 740. PubMed ID: 20718253
[No Abstract] [Full Text] [Related]
9. Spontaneous rectovaginal fistula during bevacizumab therapy for ovarian cancer: a case report.
Chéreau E; Stefanescu D; Selle F; Rouzier R; Daraï E
Am J Obstet Gynecol; 2009 Jan; 200(1):e15-6. PubMed ID: 19121652
[TBL] [Abstract][Full Text] [Related]
10. What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?
Han ES; Monk BJ
Gynecol Oncol; 2007 Apr; 105(1):3-6. PubMed ID: 17383545
[No Abstract] [Full Text] [Related]
11. Bevacizumab in the treatment of ovarian cancer.
Han ES; Monk BJ
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1339-45. PubMed ID: 17944559
[TBL] [Abstract][Full Text] [Related]
12. Angiogenesis inhibitors in the treatment of epithelial ovarian cancer.
Han ES; Wakabayashi M; Leong L
Curr Treat Options Oncol; 2013 Mar; 14(1):22-33. PubMed ID: 23288484
[TBL] [Abstract][Full Text] [Related]
13. Experience with bevacizumab in the management of epithelial ovarian cancer.
Burger RA
J Clin Oncol; 2007 Jul; 25(20):2902-8. PubMed ID: 17617521
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant bevacizumab in a granulosa cell tumor of the ovary: a case report.
Barrena Medel NI; Herzog TJ; Wright JD; Lewin SN
Anticancer Res; 2010 Nov; 30(11):4767-8. PubMed ID: 21115938
[TBL] [Abstract][Full Text] [Related]
15. Success of bevacizumab trials raises questions for future studies.
Tuma RS
J Natl Cancer Inst; 2005 Jul; 97(13):950-1. PubMed ID: 15998941
[No Abstract] [Full Text] [Related]
16. Bevacizumab as front-line treatment for newly diagnosed epithelial cancer.
González Martín A; Bratos R; Márquez R; Alonso S; Chiva L
Expert Rev Anticancer Ther; 2013 Feb; 13(2):123-9. PubMed ID: 23406552
[TBL] [Abstract][Full Text] [Related]
17. The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: where does it fit?
Eskens FA; Sleijfer S
Eur J Cancer; 2008 Nov; 44(16):2350-6. PubMed ID: 18789679
[TBL] [Abstract][Full Text] [Related]
18. Angiogenesis as a strategic target for ovarian cancer therapy.
Spannuth WA; Sood AK; Coleman RL
Nat Clin Pract Oncol; 2008 Apr; 5(4):194-204. PubMed ID: 18268546
[TBL] [Abstract][Full Text] [Related]
19. Bladder perforation in a patient with recurrent epithelial ovarian cancer after treatment with bevacizumab.
Bansal N; Hoffman M
Gynecol Oncol; 2011 Feb; 120(2):313-4. PubMed ID: 21055796
[No Abstract] [Full Text] [Related]
20. Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition.
Martin L; Schilder R
J Clin Oncol; 2007 Jul; 25(20):2894-901. PubMed ID: 17617520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
